---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004800"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-02-20T23:59:59+00:00"
generated_at: "2026-05-16T01:28:17.792201+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech raises ~$8.3M via warrant exercise inducement; issues new Series H warrants for 6.4M shares

## Summary
- Holders exercise 2,122,652 existing warrants at $3.90 per share; gross proceeds ~$8.3M.
- Company issues new Series H warrants for up to 6,367,956 shares (300% of exercised) with 5-year term.
- New warrant exercise price = lesser of $3.90 or lowest VWAP in 5 trading days post-announcement; floor $0.962.
- Shareholder approval required for issuance of new warrant shares; resale registration to be filed by March 31, 2026.
- Roth Capital served as financial advisor, receiving 7% of gross proceeds from the warrant exercise.

## SEC filing metadata
- accession: 0001437749-26-004800
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/0001437749-26-004800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/mbrx20260219_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004800
- JSON: https://secwatch.observer/filing/0001437749-26-004800.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004800.txt

## Key facts
- Material Agreements
  Moleculin Biotech, Inc. entered into Inducement Letter with holders of certain existing warrants valued at approximately $8.3 million (effective 2026-02-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: holders of certain existing warrants
  - Value: approximately $8.3 million
  - Effective: 2026-02-19
  source text: On February 19, 2026, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (each, an “Inducement Letter”) with holders of certain existing warrants (the “Holders”) to purchase up to 2,122,652 shares of Company common stock with an exercise price of $3.90 per share (the “Existing Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/0001437749-26-004800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.